Alnylam Pharmaceuticals, Inc. — 2021 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2021. Although the request references 2021 Q4, this is an annual filing; the supplied text does not provide a standalone fourth-quarter income statement or cash-flow summary.
Business context
Alnylam is a commercial-stage biopharmaceutical company developing RNA interference (RNAi) medicines. At year-end, it had three products generating its own product revenue—ONPATTRO, GIVLAARI and OXLUMO—and a fourth approved product, Leqvio, developed and commercialized by Novartis. The company reported 13 clinical programs, including five late-stage programs, and operates in four strategic therapeutic areas.
Financial performance and liquidity
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Total revenue | $844.3 million | $492.9 million | Up 71% |
| Net product revenue | $662.1 million | $361.5 million | Up 83% |
| Collaboration revenue | $181.0 million | $131.3 million | Up 38% |
| Operating expenses | $1,552.9 million | $1,321.3 million | Up 18% |
| Operating loss | $(708.7) million | $(828.4) million | Loss narrowed 14% |
| Net loss | $(852.8) million | $(858.3) million | Loss narrowed slightly |
| Net loss per share, diluted | $(7.20) | $(7.46) |
- Revenue growth reflected wider launches and more patients on ONPATTRO and GIVLAARI, plus OXLUMO sales following its 2020 approvals. 2021 product revenue comprised ONPATTRO $474.7 million, GIVLAARI $127.8 million and OXLUMO $59.6 million.
- Cost of goods sold was 17.4% of product revenue, down from 20.5% in 2020. Research and development expense rose 21% to $792.2 million; selling, general and administrative expense rose 5% to $620.6 million.
- Operating cash use was $641.7 million, compared with $615.0 million in 2020. Investing cash use was $273.3 million; financing provided $1,247.1 million, including $500 million of term-loan proceeds and $500 million from the sale of future Leqvio royalties.
- Cash, cash equivalents and marketable securities totaled $2.44 billion at year-end, versus $1.87 billion in 2020. The balance sheet reported $819.975 million of cash and cash equivalents and $1.549 billion of marketable debt securities.
- Long-term debt, net, was $675.7 million; $700 million had been drawn under the delayed-draw facility, which matures in December 2027 and bore an 8% rate at year-end. The facility is secured by specified assets and requires at least $100 million of quarterly consolidated liquidity; Alnylam reported compliance.
- The separate liability for sold future royalties was $1.188 billion, including $37.1 million current. Interest expense was $143.0 million, including $116.9 million associated with that liability. Total liabilities were $3.055 billion and stockholders’ equity was $588.2 million.
- Management said current resources and expected product, alliance and Leqvio-related receipts should fund its operating plan for at least 12 months from the filing date. The auditor issued an unqualified opinion and reported effective internal control over financial reporting.
Material changes versus the prior comparable year
- Revenue increased $351.4 million, led by product revenue growth of $300.6 million. Collaboration revenue rose $49.6 million, including a $25 million Novartis milestone following Leqvio’s U.S. approval; Alnylam also recognized $1.2 million in Leqvio royalty revenue.
- Operating expenses increased $231.6 million, with higher clinical and manufacturing costs, commercial investment and collaboration-related costs. Operating loss nevertheless narrowed; net loss was nearly unchanged as other expense increased.
- Interest expense rose to $143.0 million from $84.5 million, primarily reflecting royalty-sale financing and the term loans. A $38.4 million fair-value loss on the development derivative liability also contributed to other expense.
- Cash and marketable securities rose by approximately $570 million, supported by financing, while operating cash use increased by $26.7 million.
Outlook, management commentary and principal risks
- Strategy: Alnylam’s Alnylam P5x25 plan targets six or more marketed products, more than 0.5 million patients treated, over 20 clinical programs, revenue CAGR of at least 40% through year-end 2025, and sustainable non-GAAP profitability within the period. These are strategic targets, not guaranteed outcomes.
- 2022 outlook: Management expected product revenue to increase as patient numbers and geographic launches expanded, and combined collaboration and royalty revenue to increase moderately. R&D and SG&A were expected to rise; capital expenditures were also expected to increase. The filing gives no specific numerical 2022 revenue or expense guidance in the supplied text.
- Pipeline catalysts: Vutrisiran’s FDA action date was April 14, 2022; the company expected APOLLO-B topline results in mid-2022 and HELIOS-B results in early 2024. A Stargardt disease Phase 3 study was planned for late 2022. Sanofi moved the potential fitusiran filing date to 2024 following safety-related protocol changes.
- Material risks: Alnylam has a long history of losses and a $5.44 billion accumulated deficit, depends on continued revenue growth and collaboration receipts, and expects ongoing operating losses and investment. Commercial adoption, pricing and reimbursement, competition, clinical outcomes, regulatory review, patent protection, and manufacturing capacity could impede its plans.
- Safety and execution: COVID-19 could affect patient access, trial enrollment, inspections and supply chains. Fitusiran previously had thrombotic events and a dosing pause; revised dosing and additional safety assessment delayed its filing timetable. Third-party manufacturing concentration is a risk, including Agilent as sole API manufacturer for ONPATTRO and GIVLAARI.
- Legal and governance: The DOJ subpoena concerning U.S. marketing and promotion of ONPATTRO remained under investigation; no probable or reasonably estimable loss was recorded. A securities lawsuit settlement was agreed in principle, with court approval still pending. Founding CEO John Maraganore transitioned to Yvonne Greenstreet effective January 1, 2022.
- Unusual financing: Alnylam sold Blackstone 50% of Leqvio royalties and 75% of commercial milestones for $1 billion in aggregate. The proceeds are accounted for as a liability and generate substantial non-cash interest expense; Blackstone’s royalty share may increase if a specified payment threshold is not met by 2029.
Most important facts for investors to verify
- Whether product launches and patient growth can support the company’s ambitious revenue and profitability targets, and how much spending is required to advance the pipeline.
- Vutrisiran’s regulatory outcome and the results of cardiomyopathy studies, alongside the timing and safety profile of fitusiran development.
- Leqvio’s commercial uptake, Alnylam’s remaining royalty and milestone receipts after the Blackstone sale, and the assumptions underlying the $1.188 billion royalty-related liability.
- Cash burn, financing terms and covenants, including the $100 million minimum liquidity requirement and secured collateral.
- Developments in the DOJ ONPATTRO investigation, the pending securities settlement approval, and any related financial or operational consequences.